Presbyopic correction on the cornea

Table 4 Summary of clinical studies in PresbyMAX

Study	n	Follow-Up	UDVA	UNVA	DCNVA	CDVA	CNVA	Refr.Outc.	Retreat.	Revers.
Uthoff et al. [31]	60	6M	20/21	J3	---	13% < −2lns	0% < −2lns	73% ± 0.5DS	0%	0%
Uthoff et al. [31]	60	6M	83% > 20/25	43% > J2	---	13% < −2lns	0% < −2lns	73% ± 0.5DS	0%	0%
Luger et al. [13]	66	1Y	20/23	J1	J3	3% < −2l ns	8% < −2 lns	73% ± 0.5DS	0%	0%
Luger et al. [13]	66	1Y	70% > 20/25	84% > J2	J3	3% < −2l ns	8% < −2 lns	93% ± 0.5DC	0%	0%
Baudu [14]	716	6M	20/25	J1	J2	6% < −2l ns	1% < −2 lns	88% ± 0.5DS	14%	<1%
Baudu [14]	716	6M	76% > 20/25	90% > J2		6% < −2l ns	1% < −2 lns	99% ± 0.5DC	14%	<1%
Grand total	842	6M-1Y	20/24	J1	J3	5% < −2lns	3% < −2lns	85% ± 0.5DS	10%	1%
Grand total	842	6M-1Y	77% > 20/25	90% > J2	38% > +2lns	5% < −2lns	3% < −2lns	98% ± 0.5DC	10%	1%

UDVA: uncorrected distance visual acuity, UNVA: uncorrected near visual acuity, n: number of patients in the study, DCNVA: distance-corrected near visual acuity, CDVA: corrected distance visual acuity; CNVA: corrected near visual acuity, Refr. Outc.: refractive outcome; Retreat.: retreatment rate, Revers.: percentage of reverse treatment, M: months, Y: year, J: Jaeger scale for near vision, lns: Snellen lines, DS: dioptre sphere, DC: dioptre cylinder.

ISSN: 2326-0254